Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Receives $14.83 Average Target Price from Analysts

Shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA) have been assigned an average recommendation of “Moderate Buy” from the six research firms that are currently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and five have given a buy recommendation to the company. The average twelve-month price target among brokers that have issued ratings on the stock in the last year is $14.8333.

Several research firms have recently commented on IVA. Guggenheim raised their price target on Inventiva from $9.00 to $13.00 and gave the company a “buy” rating in a report on Tuesday, September 2nd. HC Wainwright began coverage on Inventiva in a report on Wednesday, September 3rd. They issued a “buy” rating and a $20.00 price target for the company. Finally, Piper Sandler assumed coverage on Inventiva in a report on Wednesday, August 27th. They issued an “overweight” rating and a $26.00 price target for the company.

Hedge Funds Weigh In On Inventiva

An institutional investor recently bought a new position in Inventiva stock. Wealth Enhancement Advisory Services LLC acquired a new stake in Inventiva S.A. Sponsored ADR (NASDAQ:IVA) in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 10,715 shares of the company’s stock, valued at approximately $32,000. Institutional investors own 19.06% of the company’s stock.

Inventiva Price Performance

IVA opened at $5.67 on Friday. The business has a 50 day simple moving average of $4.46 and a 200-day simple moving average of $3.68. Inventiva has a 12 month low of $1.53 and a 12 month high of $6.50.

Inventiva Company Profile

Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.